• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Acorda Therapeutics announces new supply agreement with Catalent for manufacture of Inbrija inhaled dry powder levodopa

Acorda Therapeutics announced that it has signed a new supply agreement with Catalent that reduces the amount of product that the company is required to buy annually from $18 million to $8.5 million for 2023 and $15.5 million for 2024. From 2025 on, the announcement says, Acorda will pay a fixed amount per capsule "based on the amount of Inbrija needed in the US and … [Read more...] about Acorda Therapeutics announces new supply agreement with Catalent for manufacture of Inbrija inhaled dry powder levodopa

Cipla invests €15 million in inhaled mRNA developer Ethris

Cipla has announced a €15 million equity investment in inhaled mRNA developer Ethris. In February 2022, Ethris announced that it had closed a $26.3 million Series B financing round with proceeds going to support its ETH47 nebulized antiviral and ETH42 inhaled therapy for the treatment of primary ciliary dyskinesia. The company is also developing an inhaled mRNA … [Read more...] about Cipla invests €15 million in inhaled mRNA developer Ethris

Researchers at the Centenary Institute and the University of Sydney get grant of almost AU$1 million for development of intranasal vaccine against COVID-19

According to the Centenary Institute, the New South Wales COVID-19 Vaccine Acceleration Research Grants Program has awarded a grant worth AU$995,867 to researchers at the Centenary Institute and the University of Sydney to support development of an intranasal vaccine against COVID-19. Sydney-based Ab Initio Pharma, which was recently granted a license to manufacture … [Read more...] about Researchers at the Centenary Institute and the University of Sydney get grant of almost AU$1 million for development of intranasal vaccine against COVID-19

Vistagen announces agreement to acquire Pherin Pharmaceuticals

Vistagen, which is developing two pherine-based nasal sprays licensed from Pherin Pharmaceuticals (PH10 and PH94B), announced that it has reached an agreement to acquire Pherin and its entire pipeline. According to Vistagen, the deal includes ~12.4 million shares of the company's common stock as well as "a nominal amount of cash." PH10 was recently granted Fast … [Read more...] about Vistagen announces agreement to acquire Pherin Pharmaceuticals

Third Pole gets $32 million to support development of eNOcare inhaled nitric oxide device

Inhaled nitric oxide (iNO) delivery device developer Third Pole Therapeutics announced that it has received a $32 million equity investment "from a large medical device innovator." In February 2022, the company announced the closing of a $25 million financing. Chiesi acquired global rights to develop and commercialize Third Pole's tankless iNO technology in April … [Read more...] about Third Pole gets $32 million to support development of eNOcare inhaled nitric oxide device

CF Foundation invests $4.85 million in Aridis Pharmaceuticals to support development of AR-501 inhaled gallium

According to Aridis Pharmaceuticals, the Cystic Fibrosis Foundation has made a $4.85 million investment in Aridis common stock to support continued development of AR-501 nebulized gallium citrate for the treatment of chronic lung infections in CF patients, bringing the CF Foundation's total funding for the project to $12.5 million. AR-501 has been granted orphan, … [Read more...] about CF Foundation invests $4.85 million in Aridis Pharmaceuticals to support development of AR-501 inhaled gallium

Evoke gets new US patent covering Gimoti metoclopramide nasal spray

According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a new patent covering Evoke's Gimoti metoclopramide nasal spray. The new patent (No. 11,517,545), which expires in 2038, is titled "Treatment of Moderate and Severe Gastroparesis." The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020 and granted 3 … [Read more...] about Evoke gets new US patent covering Gimoti metoclopramide nasal spray

Pulmocide raises $52 million for further development of inhaled opelconazole

Pulmocide announced that it has closed a $52 million a Series C extension round, with the proceeds to be used for continued development of its PC945 inhaled opelconazole for the treatment of invasive pulmonary Aspergillosis (IPA). Opelconazole has been granted orphan drug, Fast Track, and Qualified Infectious Disease Product designations. In December 2021, … [Read more...] about Pulmocide raises $52 million for further development of inhaled opelconazole

Vistagen announces planned Phase 1 trial of new formulation of PH10 nasal spray

After receiving a "Study May Proceed" letter from the FDA, Vistagen has announced plans for a Phase 1 trial of a re-formulated version of PH10 pherin nasal spray. The new Phase 1 study is expected to begin in early 2023 as part of plans to develop the nasal spray for the treatment of major depressive disorder. A previous Phase 2a trial of PH10 for that indication … [Read more...] about Vistagen announces planned Phase 1 trial of new formulation of PH10 nasal spray

Nuance Pharma takes steps towards marketing Bentrio nasal spray in Hong Kong and Macau

Nuance Pharma has announced a deal with DKSH Business Unit Healthcare for commercialization of Bentrio, an API-free, bentonite-based OTC nasal spray for protection against allergens and viruses, in Hong Kong and Macau. Bentrio is currently marketed in several countries in Europe for allergic rhinitis, and in the US, the nasal spray received 510(k) clearance in June … [Read more...] about Nuance Pharma takes steps towards marketing Bentrio nasal spray in Hong Kong and Macau

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews